Burning Rock Biotech (NASDAQ:BNR) on Thursday reported unaudited financial results for the fourth quarter and full year ended December 31, 2025, showing modest top-line growth alongside significant margin expansion and cost discipline in its precision oncology testing business.
Full-year revenue increased 4.6% year over year to RMB539.6 million (US$77.2 million).
Fourth-quarter revenue totaled RMB126.3 million (US$18.1 million).
Gross margin for the full year rose to 74.7%, reflecting improved cost efficiencies in laboratory operations and a favorable mix of higher-margin central laboratory and in-hospital testing services.
Operating expenses declined 36.4% year over year, driven by targeted cost reductions across R&D, sales and marketing, and general administrative functions following strategic streamlining efforts.
Elsewhere, the company highlighted several key operational advancements during the period, including the grant of a U.S. Patent and Trademark Office patent for its ELSA-seq (Enrichment-based Library Sequencing for Allele-specific detection) technology, which enhances detection of low-frequency variants in liquid biopsy samples.